As of 2024-12-12, the EV/EBITDA ratio of Halozyme Therapeutics Inc (HALO) is 11.81. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HALO's latest enterprise value is 7,435.25 mil USD. HALO's TTM EBITDA according to its financial statements is 629.62 mil USD. Dividing these 2 quantities gives us the above HALO EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 15.6x - 19.2x | 16.8x |
| Forward P/E multiples | 16.7x - 26.1x | 20.9x |
| Fair Price | 46.97 - 84.31 | 67.08 |
| Upside | -1.8% - 76.3% | 40.2% |
| Date | EV/EBITDA |
| 2024-12-11 | 11.76 |
| 2024-12-10 | 12.06 |
| 2024-12-09 | 12.06 |
| 2024-12-06 | 11.92 |
| 2024-12-05 | 11.86 |
| 2024-12-04 | 11.97 |
| 2024-12-03 | 11.94 |
| 2024-12-02 | 11.96 |
| 2024-11-29 | 11.88 |
| 2024-11-27 | 11.94 |
| 2024-11-26 | 11.80 |
| 2024-11-25 | 11.80 |
| 2024-11-22 | 12.05 |
| 2024-11-21 | 11.38 |
| 2024-11-20 | 11.39 |
| 2024-11-19 | 11.20 |
| 2024-11-18 | 10.75 |
| 2024-11-15 | 11.37 |
| 2024-11-14 | 13.05 |
| 2024-11-13 | 13.99 |
| 2024-11-12 | 14.19 |
| 2024-11-11 | 14.49 |
| 2024-11-08 | 14.47 |
| 2024-11-07 | 14.20 |
| 2024-11-06 | 14.40 |
| 2024-11-05 | 14.01 |
| 2024-11-04 | 13.96 |
| 2024-11-01 | 13.69 |
| 2024-10-31 | 12.36 |
| 2024-10-30 | 12.37 |
| 2024-10-29 | 12.38 |
| 2024-10-28 | 12.34 |
| 2024-10-25 | 12.10 |
| 2024-10-24 | 12.11 |
| 2024-10-23 | 12.41 |
| 2024-10-22 | 12.56 |
| 2024-10-21 | 12.61 |
| 2024-10-18 | 12.77 |
| 2024-10-17 | 12.71 |
| 2024-10-16 | 12.95 |
| 2024-10-15 | 13.02 |
| 2024-10-14 | 13.05 |
| 2024-10-11 | 12.85 |
| 2024-10-10 | 12.68 |
| 2024-10-09 | 12.38 |
| 2024-10-08 | 13.08 |
| 2024-10-07 | 13.03 |
| 2024-10-04 | 14.10 |
| 2024-10-03 | 14.36 |
| 2024-10-02 | 13.90 |